Search

Your search keyword '"Scadding, Glenis K."' showing total 10 results
Start Over Author "Scadding, Glenis K." Publisher elsevier
10 results on '"Scadding, Glenis K."'

2. Contributors

Author

Ahmed, Asia A., primary, Albert, Richard K., additional, Allen, Mark S., additional, Arenberg, Douglas, additional, Bearfield, Phil, additional, Benfield, Thomas, additional, Berim, Ilya, additional, Bird, Kathryn G., additional, Birring, Surinder S., additional, Brander, Lukas, additional, Brown, Jeremy S., additional, Brown, Kevin K., additional, Bull, Todd M., additional, Burgos, Felip, additional, Calverley, Peter M.A., additional, Camus, Philippe, additional, Carbonara, Paolo, additional, Carlos, William Graham, additional, Cassivi, Stephen D., additional, Cavallazzi, Rodrigo, additional, Celli, Bartolome R., additional, Chang, William Y.C., additional, Chow, Chung-Wai, additional, Churg, Andrew M., additional, Cordier, Jean-François, additional, Cosio, Borja G., additional, Cottin, Vincent, additional, Culver, Bruce H., additional, Daley, Charles L., additional, Davies, Helen E., additional, Denlinger, Chadrick E., additional, Deroose, Christophe, additional, Deschamps, Claude, additional, Dooms, Christophe, additional, Downey, Gregory P., additional, Ferrer, Miquel, additional, Folz, Rodney J., additional, Garrity, Edward R., additional, Gifford, Alex H., additional, Glenny, Robb W., additional, Gray, Kelsey, additional, Green, Ruth H., additional, Gruber, Michael P., additional, Grutters, J.C., additional, Haas, Andrew R., additional, Hage, Chadi A., additional, Haldar, Pranabashis, additional, Hansell, David M., additional, Hart, Nicholas, additional, Herth, Felix J.F., additional, Highland, Kristin B., additional, Holmes, Andre, additional, Hurst, John R., additional, Iannuzzi, Michael C., additional, Barbé, Ferrán, additional, Jardin, Cyrielle, additional, Johnson, Simon R., additional, Kacmarek, Robert M., additional, Kariyawasam, Harsha H., additional, Kaufman, Joel D., additional, Kreit, John W., additional, Krowka, Michael J., additional, Lambert, Mark, additional, Lammers, J.-W.J., additional, Lapinsky, Stephen E., additional, Lee, Y.C. Gary, additional, Bassi, Gianluigi Li, additional, Lipman, Marc C.I., additional, Lomas, David A., additional, MacNee, William, additional, Mahler, Donald A., additional, Malo, Jean-Luc, additional, Marciniak, Stefan J., additional, Marin, José M., additional, Martínez-García, Miguel Ángel, additional, Mazzone, Peter, additional, McGlennan, Alan, additional, McShane, Pamela J., additional, Meniawy, Tarek, additional, Midthun, David E., additional, Miller, Robert F., additional, Moraes, Theo J., additional, Morris, Alison, additional, Mwenge, Gimbada B., additional, Nava, Stefano, additional, Newman, Lee S., additional, Okcay, Aynur, additional, Padley, Simon P.G., additional, Parameswaran, Ganapathi Iyer, additional, Pastis, Nicholas J., additional, Paul, Manju, additional, Pavord, Ian D., additional, Petersen, Hilary, additional, Polkey, Michael I., additional, Quint, Jennifer, additional, Rabe, Klaus F., additional, Ramsay, Michelle, additional, Ratjen, Felix, additional, Rezaei, M. Katayoon, additional, Rinne, Seppo T., additional, Robinson, Bruce W.S., additional, Roca, Josep, additional, Rodenstein, Daniel, additional, Rosado, Jaime Rodríguez, additional, Rosado-de-Christenson, Melissa L., additional, Rose, Cecile, additional, Rossi, Federico Fiorentino, additional, Ruiz, Luis G., additional, Scadding, Glenis K., additional, Schneider, Frank, additional, Schwartz, Arnold M., additional, Sergew, Amen, additional, Sethi, Sanjay, additional, Shaw, Penny J., additional, Simonds, Anita K., additional, Slutsky, Arthur S., additional, Specks, Ulrich, additional, Spiro, Jonathan R., additional, Spiro, Michael, additional, Spiro, Stephen G., additional, Steeds, Richard P., additional, Sterman, Daniel H., additional, Stinson, Kaylan E., additional, Stockley, Robert, additional, Strollo, Diane C., additional, Sulemanji, Demet S., additional, Tanoue, Lynn, additional, Taylor, Magali N., additional, Torres, Antoni, additional, Tullis, Elizabeth, additional, Vachani, Anil, additional, Vandenplas, Olivier, additional, Vansteenkiste, Johan, additional, Vassilakopoulos, Theodoros, additional, Veraldi, Kristen L., additional, Villar, Jesús, additional, Wagner, Peter D., additional, Wallaert, Benoit, additional, Walter, Nicholas, additional, Wedzicha, Jadwiga A., additional, Wells, Athol, additional, Whitters, Deborah, additional, Woodhead, Mark A., additional, Wright, Joanne L., additional, and Wrightson, John M., additional

Published
2012
Full Text
View/download PDF

3. list of contributors

Author

Adachi, Mitsuru, primary, Austin, Sarah, additional, Bielory, Leonard, additional, Bischoff, Stephan C, additional, Boner, Attilio L, additional, Borish, Larry, additional, Boschetto, Piera, additional, Broide, David H, additional, Busse, William W, additional, Calder, Virginia L, additional, Casale, Thomas B, additional, Church, Martin K, additional, Corren, Jonathan, additional, Creticos, Peter S, additional, Custovic, Adnan, additional, DeBrosse, Charles W, additional, Demoly, Pascal, additional, Durham, Stephen R, additional, Dykewicz, Mark S, additional, Ewan, Pamela W, additional, Grattan, Clive EH, additional, Gruchalla, Rebecca S, additional, Hingorani, Melanie, additional, Holgate, Stephen T, additional, Holloway, John W, additional, Holt, Patrick G, additional, Kapp, Alexander, additional, Lieberman, Phil, additional, Lightman, Susan, additional, Ludwig, Martha, additional, Maestrelli, Piero, additional, Malling, Hans-Jorgen, additional, Martinez, Fernando D, additional, Maurer, Marcus, additional, Metcalfe, Dean D, additional, Naisbitt, Dean J, additional, Oettgen, Hans, additional, Park, B Kevin, additional, Peden, David B, additional, Peebles, R Stokes, additional, Platts-Mills, Thomas AE, additional, Prescott, Susan, additional, Rothenberg, Marc E, additional, Sampson, Hugh A, additional, Scadding, Glenis K, additional, Sly, Peter D, additional, Stewart, Geoffrey A, additional, Thompson, Philip J, additional, Valent, Peter, additional, von Mutius, Erika, additional, Warner, John O, additional, Werfel, Thomas, additional, and Zuraw, Bruce L, additional

Published
2012
Full Text
View/download PDF

6. Contributors

Author

Albert, Richard K., primary, Allen, Mark S., additional, Atwood, Charles W., additional, Aubry, Marie Christine, additional, Barker, Alan F., additional, Barnes, Peter J., additional, Benfield, Thomas, additional, Birring, Surinder S., additional, Bolliger, Chris T., additional, Brander, Lukas, additional, Brower, Roy G., additional, Brown, Jeremy, additional, Bull, Todd M., additional, Camus, Philippe, additional, Carlsten, Christopher, additional, Cassivi, Stephen D., additional, Chan-Yeung, Moira, additional, Chia, Jessica Y., additional, Chow, Chung-Wai, additional, Colby, Thomas V., additional, Coldren, Christopher D., additional, Cordier, Jean-François, additional, Costabel, Ulrich, additional, Cottin, Vincent, additional, Criner, Gerard J., additional, Culver, Bruce H., additional, Daley, Charles L., additional, Davies, Helen E., additional, Decramer, Marc, additional, Deschamps, Claude, additional, Diacon, Andreas H., additional, Dooms, Christophe, additional, Dougherty, Ryan H., additional, Douglas, Neil J., additional, Downey, Gregory P., additional, Evans, Scott E., additional, Evans, Timothy W., additional, Fitting, Jean-William, additional, Folz, Rodney J., additional, Garrity, Edward R., additional, Gehlbach, Brian K., additional, Geraci, Mark W., additional, Gosselink, Rik, additional, Brigitte Gottschall, E., additional, Gruber, Michael P., additional, Grutters, J.C., additional, Hall, Jesse B., additional, Hansell, David M., additional, Hansra, Inderjit K., additional, Herth, Felix J.F., additional, Hill, Nicholas S., additional, Hines, Stella E., additional, Hubbard, Richard, additional, Huchon, Gérard J., additional, Hudson, Leonard D., additional, Hurst, John R., additional, Iannuzzi, Michael C., additional, Jett, James R., additional, Kaufman, Joel D., additional, Kim, Victor, additional, Koegelenberg, Coenraad F.N., additional, Kreit, John W., additional, Krowka, Michael J., additional, Langer, Daniel, additional, Lapinsky, Stephen E., additional, Lazarus, Stephen C., additional, Gary Lee, Y.C., additional, Leroy, Sylvie, additional, Lipman, Marc C.I., additional, MacNee, William, additional, Malo, Jean-Luc, additional, M. McGhan, Ryan, additional, McKinley, Sarah, additional, Midthun, David E., additional, Miller, Robert F., additional, Moraes, Theo J., additional, Myers, Jeffrey L., additional, Neff, Margaret J., additional, Newman, Lee S., additional, Olson, Eric J., additional, Padley, Simon P.G., additional, Partridge, Martyn R., additional, Pavord, Ian D., additional, Porter, Joanna C., additional, Rabbat, Antoine, additional, Ratjen, Felix, additional, Reed, Anna K., additional, Rosado-de-Christenson, Melissa L., additional, Rose, Cecile S., additional, Roussos, Charis, additional, Ruiz, Luis G., additional, Ryu, Jay H., additional, Scadding, Glenis K., additional, Scanlon, Paul D., additional, Schane, Rebecca E., additional, Schwarz, Marvin I., additional, Sebastian, Fabian, additional, Sevransky, Jonathan E., additional, Shah, Lori, additional, Shaw, Penny, additional, W. Shimabukuro, David, additional, Sietsema, Kathy E., additional, Simonds, Anita K., additional, Slutsky, Arthur S., additional, Spiro, Stephen G., additional, Sterman, Daniel H., additional, Stinson, Kaylan E., additional, Strollo, Diane C., additional, Strollo, Patrick J., additional, Sue, Darryl Y., additional, Teirstein, Alvin S., additional, Torres, Antoni, additional, Troosters, Thierry, additional, Tullis, Elizabeth, additional, Vachani, Anil, additional, Valencia, Mauricio, additional, van den Bosch, J.M.M., additional, Vansteenkiste, Johan, additional, Vassilakopoulos, Theodoros, additional, Wallaert, Benoit, additional, Wedzicha, Jadwiga A., additional, Wells, Athol, additional, White, Dorothy A., additional, Wiener-Kronish, Jeanine P., additional, Woodhead, Mark A., additional, Woodruff, Prescott G., additional, Wort, Stephen J., additional, and Wynants, Jokke, additional

Published
2008
Full Text
View/download PDF

8. Audit of nasal lysine aspirin therapy in recalcitrant aspirin exacerbated respiratory disease

Author

Howe, Rachel, Mirakian, Rita M, Pillai, Prathap, Gane, Simon, Darby, Yvonne C, and Scadding, Glenis K

Subjects
lcsh:Immunologic diseases. Allergy, Immunology and Allergy, lcsh:RC581-607
Abstract

Background Aspirin – exacerbated respiratory disease can prove difficult to control. Oral aspirin desensitization is effective, but has adverse effects and may not be cardio-protective at the high doses needed.Objective To examine the effectiveness of aspirin administered in lower doses via the nose.Methods An audit of 121 patients with aspirin exacerbated respiratory disease (AERD), 105 of whom were treated with intranasal lysine aspirin in gradually increasing doses following positive lysine aspirin challenge.Results Treatment was associated with subjective symptomatic improvement or stabilization in 60 of 78 patients at 3 months and 19 of 27 at 12 months. Nasal inspiratory peak flow, olfaction, exhaled and nasal nitric oxide levels were significantly improved (p < 0.05 for all). Patients with positive skin prick tests and those with later onset (>40 years) AERD improved more than non-atopics and those with early onset AERD.Asthma outcomes over 1 year were assessed by questionnaire in 22 patients on lysine aspirin and in 20 who were positive on challenge but who either refused treatment or took it only briefly (less than or equal to 3 months). There was a significant decrease in emergency visits (p = 0.0182), hospitalization (p = 0.0074) and oral steroid use (p = 0.004) in those on nasal lysine aspirin for a year.Gastrointestinal side effects occurred in 3.8%, lower than those reported for oral aspirin therapy. Conclusions and Clinical Relevance This form of therapy might reduce the need for expensive monoclonal antibodies in AERD patients. Keywords: Aspirin exacerbated respiratory disease, Lysine aspirin, Nasal polyposis, Late onset asthma

Published
2014

9. EUFOREA pocket guide on the diagnosis and management of asthma: An educational and practical tool for general practitioners, non-respiratory physicians, paramedics and patients.

Author

Diamant Z, Jesenak M, Hanania NA, Heaney LG, Djukanovic R, Ryan D, Quirce S, Backer V, Gaga M, Pavord I, Antolín-Amérigo D, Assaf S, Bakakos P, Bobcakova A, Busse W, Kappen J, Loukides S, van Maaren M, Panzner P, Pite H, Spanevello A, Stenberg H, Striz I, Thio B, Vasakova MK, Conti D, Fokkens W, Lau S, Scadding GK, Van Staeyen E, Hellings PW, and Bjermer L

Subjects
Humans, Paramedics, Educational Status, Patients, General Practitioners, Asthma diagnosis, Asthma therapy
Abstract

Competing Interests: Declaration of competing interest ZD: received consultancy fees/lecture fees/fees for attending advisory boards from ALK, Antabio, Foresee Pharmaceuticals, GlaxoSmithKline, Hippo-Dx, QPS-Netherlands, Sanofi-Genzyme; she served as Director Respiratory & Allergy at QPS-NL and this CRO received research grants for clinical trials from HAL Allergy, Janssen Research & Development LLC, Patara pharma, Cerbios, Merck Sharp & Dohme, Novartis, Foresee Pharmaceuticals and ERA4TB (IMI-project). MJ: ALK, Stallergenes-Greer, Chiesi, GSK, Pfizer, Novartis, AstraZeneca and SANOFI. NH: Received honoraria for serving as advisor or consultant for GSK, AstraZeneca, Sanofi, Regeneron, Amgen, Genentech, Novartis and Teva. His institution received research grant support of his behalf from GSK, Genentech, Sanofi, Teva, Novartis, and AstraZeneca. LH: Has received grant funding, participated in advisory boards and given lectures at meetings supported by Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, Circassia, Hoffmann la Roche, GlaxoSmithKline, Novartis, Theravance, Evelo Biosciences, Sanofi, and Teva; he has received grants from MedImmune, Novartis UK, Roche/ Genentech Inc, and Glaxo Smith Kline, Amgen, Genentech/Hoffman la Roche, Astra Zeneca, MedImmune, Glaxo Smith Kline, Aerocrine and Vitalograph; he has received sponsorship for attending international scientific meetings from AstraZeneca, Boehringer Ingelheim, Chiesi, GSK and Napp Pharmaceuticals; he has also taken part in asthma clinical trials sponsored by AstraZeneca, Boehringer Ingelheim, Hoffmann la Roche, and GlaxoSmithKline for which his institution received remuneration; he is the Academic Lead for the Medical Research Council Stratified Medicine UK Consortium in Severe Asthma which involves industrial partnerships with a number of pharmaceutical companies including Amgen, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Hoffmann la Roche, and Janssen. RD: Declares consulting fees from Synairgen, Sanofi and Galapagos, lecture fees from GSK, AZ and Airways Vista and he holds shares from Synairgen. DR: No COIs related to this work. SQ: ALK, Allergy Therapeutics, AstraZeneca, Chiesi, GSK, Leti, Mundipharma, Novartis, Sanofi-Genzyme, Teva. VB: Has worked as advisor, supervisor, investigator of pharmaceutical studies, unrestricted grants, and others with: AstraZeneca, GSK, MSD & Shering Plough, ALK-Abello; Chiesi,Novartis, Pharmaxis, Pfizer, Boehringer Ingelheim, Aerocrine, Teva, Sanofi, Birk NPC as. MG: No COIs related to this work. IP: In the last 5 years IDP has received speaker’s honoraria for speaking at sponsored meetings from Astra Zeneca, Boehringer Ingelheim, Aerocrine, Almirall, Novartis, Teva, Chiesi, Sanofi/Regeneron, Menarini and GSK and payments for organising educational events from AZ, GSK, Sanofi/Regeneron and Teva. He has received honoraria for attending advisory panels with Genentech, Sanofi/ Regeneron, Astra Zeneca, Boehringer Ingelheim, GSK, Novartis, Teva, Merck, Circassia, Chiesi and Knopp and payments to support FDA approval meetings from GSK. He has received sponsorship to attend international scientific meetings from Boehringer Ingelheim, GSK, AstraZeneca, Teva and Chiesi. He has received a grant from Chiesi to support a phase 2 clinical trial in Oxford. DAA: Has received honoraria as grants/contracts from Sociedad Española de Alergología e Inmunología Clínica (SEAIC), as consulting fees from ALK-Abelló, AstraZeneca, Chiesi and Gebro, as speaker from AstraZeneca, Chiesi, Gebro, GSK, Leti Pharma, Mundipharma, Novartis, Roxall, Sanofi. AS: GSK support for an asthma biologic clinical trial 2021-ongoing. PB: Has received honoraria for presentations and consultancy fees from AstraZeneca, Boehringer Ingelheim, Chiesi, ELPEN, GSK, Menarini, Novartis, Sanofi, and Gilead. AB: Takeda, Novartis, Viatris, ALK, Zentiva, MERCK, Stallergenes Greer, Ewopharma, Astra Zeneca, Chiesi, S&D Pharma, Mundipharma, Berlin Chemie. WB: GlaxoSmithKline, Sanofi, Regeneron. JK: Grants and/or personal fees from ALK, Chiesi, GSK, Novartis, AstraZeneca, Sanofi, Boerhinger, Teva, Viatris, Stallergen, Abbot, all outside the submitted work. SL: Honorarium AstraZeneka, GSK, Chiesi Hellas, Sanofi, Elpen, Menarini, Guidoti. MVM: No COIs related to this work. PP: ALK, AstraZeneca, Stallergenes. HP: No COIs related to this work. AS: Reports lecture fees and/or consultancies from AstraZeneca, Chiesi, B.I., GSK, Merck, Novartis, Zambon, Sanofi. HS: No COIs related to this work. IS: No COIs related to this work. BT: No COIs related to this work. MKV: GlaxoSmithKline, AstraZeneca. Diego Conti: No COIs related to this work. WF: The department of Otorhinolaryngology of the Amsterdam University Medical centre, location AMC received grants for research in Rhinology from: ALK, AllergyTherapeutics, Novartis, EU, GSK, MYLAN, Sanofi-Aventis, and Zon-MW; personal COIs: for consultation and/or speaker fees from Dianosic, GSK, Novartis and Sanofi-Aventis/Regeneron. SL: Advisory Board Sanof-Aventis, GSK and Leo-Pharma. Honoraria by DBV Technologies, Allergopharma, Leti, Nutricia, Sanofi-Aventis. GKS: Honoraria for articles, speaker and advisory boards: ALK, AstraZeneca, Capnia, Church & Dwight, Circassia, Noucor, GSK, Meda/Mylan/Viatris, Merck, Sanofi- Regeneron, Stallergenes. Scientific Chief Editor, Rhinology Section, Frontiers in Allergy. Board Member, Lead for Allergic Rhinitis, EUFOREA. Chair of Data Monitoring Board for Paediatric AR trials of HDM SLIT. EVS: No COIs related to this work. PH: Recipient of research grants, honoraria and/or lecture fees of Sanofi, Regeneron, Viatris, GSK, and Novartis. LB: No COIs related to this work.

Published
2023
Full Text
View/download PDF

10. Allergic rhinitis.

Author

Greiner AN, Hellings PW, Rotiroti G, and Scadding GK

Subjects
Asthma etiology, Diagnosis, Differential, Humans, Occupational Diseases etiology, Rhinitis, Allergic, Perennial complications, Rhinitis, Allergic, Perennial diagnosis, Rhinitis, Allergic, Perennial physiopathology, Rhinitis, Allergic, Perennial therapy, Rhinitis, Allergic, Seasonal complications, Rhinitis, Allergic, Seasonal diagnosis, Rhinitis, Allergic, Seasonal physiopathology, Rhinitis, Allergic, Seasonal therapy
Abstract

Allergic rhinitis is a very common disorder that affects people of all ages, peaking in the teenage years. It is frequently ignored, underdiagnosed, misdiagnosed, and mistreated, which not only is detrimental to health but also has societal costs. Although allergic rhinitis is not a serious illness, it is clinically relevant because it underlies many complications, is a major risk factor for poor asthma control, and affects quality of life and productivity at work or school. Management of allergic rhinitis is best when directed by guidelines. A diagnostic trial of a pharmacotherapeutic agent could be started in people with clinically identified allergic rhinitis; however, to confirm the diagnosis, specific IgE reactivity needs to be recorded. Documented IgE reactivity has the added benefit of guiding implementation of environmental controls, which could substantially ameliorate symptoms of allergic rhinitis and might prevent development of asthma, especially in an occupational setting. Many classes of drug are available, effective, and safe. In meta-analyses, intranasal corticosteroids are superior to other treatments, have a good safety profile, and treat all symptoms of allergic rhinitis effectively. First-generation antihistamines are associated with sedation, psychomotor retardation, and reduced academic performance. Only immunotherapy with individually targeted allergens has the potential to alter the natural history of allergic rhinitis. Patients' education is a vital component of treatment. Even with the best pharmacotherapy, one in five affected individuals remains highly symptomatic, and further research is needed in this area., (Copyright © 2011 Elsevier Ltd. All rights reserved.)

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results